eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

THE BOOTS COMPANY PLC

1 Thane Road West, Beeston, Nottingham, NG2 3AA
Telephone: +44 (0)1159 595 165
Fax: +44 (0)1159 592 565

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 04/04/2012
SPC Boots Rehydration Treatment


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Replavite

Rehydration Treatment

Care Rehydration Treatment

Superdrug Blackcurrant Flavour Rehydration Treatment

Imodium Rehydration Salts


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each sachet contains:

Dextrose MonohydrateBP3.580 g
Sodium ChlorideBP0.470 g
Sodium Citrate DihydrateBP0.390 g
Potassium ChlorideBP0.300 g
Citric Acid AnhydrousBP0.128 g

Go to top of the page
3. PHARMACEUTICAL FORM

Granules to be reconstituted for oral administration.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For the treatment of acute diarrhoea and the treatment and prevention of dehydration by replacing fluids and electrolytes lost through diarrhoea.


Go to top of the page
4.2 Posology and method of administration

Adults, the elderly and children over 12 years:

The contents of one or two sachets to be taken after each loose motion.

Children 1 to 12 years:

The contents of one sachet to be taken after each loose motion.

Infants under 1 year:

Not to be given unless instructed by a doctor, in which case one to one and a half the usual 24 hour feed volume should be given.

During the first 24 hours of illness Replavite should replace normal feeds in bottle fed babies, gradually resuming normal feeds as the baby gets better. In breast fed babies, firstly the recommended amount of Replavite should be given and then breast fed until satisfactory.

Reconstitution

The contents of each sachet should be dissolved in 200 ml (7 fluid ounces) of fresh drinking water (adults and children). Freshly boiled and cooled water should be used for infants and when fresh water is not available. The solution should be made up immediately before use and used within one hour. If refrigerated the solution can be kept for up to 24 hours.

A doctor should be consulted if symptoms persist for longer than 24 – 48 hours.


Go to top of the page
4.3 Contraindications

Contraindicated in patients with phenylketonuria or those with hypersensitivity to any of the ingredients.

Oral treatment is inappropriate in such conditions as severe dehydration, which requires parenteral fluid therapy or intestinal obstruction.


Go to top of the page
4.4 Special warnings and precautions for use

Severe and persistent diarrhoea should be treated under medical supervision. If symptoms persist for more than 24 – 48 hours, medical advice should be sought. Inability to drink or retain fluids requires medical supervision.

Children

• Rehydration treatment should only be given to children under 1 year of age on medical advice.

• If a young child (particularly one under 6 months of age) has diarrhoea and/or vomiting advice should be sought from a pharmacist, doctor or other health care professional. If the diarrhoea and/or vomiting is severe the child should be seen by a doctor as soon as possible.

Renal Impairment

• Medical supervision is necessary in patients with renal disease, including anuria and prolonged oliguria.

Hepatic Impairment : Low potassium or Sodium diets: Diabetes

• Treatment should be supervised by a physician.

This product contains dextrose. Patients with rare-glucose-galactose malabsorption should not take this medicine.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None stated.


Go to top of the page
4.6 Pregnancy and lactation

May be used during pregnancy and lactation as there are no known adverse effects.


Go to top of the page
4.7 Effects on ability to drive and use machines

None stated.


Go to top of the page
4.8 Undesirable effects

None stated.


Go to top of the page
4.9 Overdose

If significant overdosage occurs, serum and electrolytes should be evaluated. Corrective measures should be carried out and levels monitored until a return to normal levels is achieved.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

The product consists of physiological salts and glucose, which are used synergistically in solution to aid rehydration. The pharmacodynamic effect is to counter the drop in the extracellular fluid volume and electrolytes in mild to moderate diarrhoea.


Go to top of the page
5.2 Pharmacokinetic properties

None relevant.


Go to top of the page
5.3 Preclinical safety data

None stated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Colloidal Anhydrous Silica BP

Aspartame (which contains Phenylalanine)

Blackcurrant Flavourings


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

The granules have a two year shelf life.

The reconstituted solution should be discarded after 1 hour or 24 hours if stored in a refrigerator.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C in a dry place.


Go to top of the page
6.5 Nature and contents of container

Foil laminate sachets

or

paper (outer surface layer) /polyethylene (outer layer) /aluminium foil (outer layer) /ionomer resin (inner layer) sachets


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Wrafton Laboratories Limited

Wrafton

Braunton

North Devon

EX33 2DL.

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 12063/0046.


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

26 November 2003.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

14 March 2012 (change to sections 4.3 and 4.4)



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/23463/SPC/